


MASTER 2 BMC  
PARCOURS GENOPATH  
ANNÉE 2021-2022




Vincent Vanoosthuyse, DR2 CNRS : [vincent.vanoosthuyse@ens-lyon.fr](mailto:vincent.vanoosthuyse@ens-lyon.fr)

Équipe P. Bernard, LBMC, ENS-Lyon :  
<http://www.ens-lyon.fr/LBMC/equipes/architecture-et-dynamique-fonctionnelle-des-chromosomes>

Langues parlées : Anglais/Français

**A new innovative approach to understand the primary roles of R-loops in human cells.**




R-loops are three-stranded by-products of transcription that result from the abnormal annealing of the nascent RNA to its DNA template (1). Although most R-loops are well tolerated in normal cells (2), changes to the prevalence and distribution of R-loops are predicted to increase genome instability in cancer and it was proposed recently that to modulate R-loop levels could constitute a promising therapeutic strategy in synergy with other cancer treatments (3, 4). It is therefore essential to understand the *primary consequences* of R-loop formation on the surrounding chromatin and to identify the R-loops with the greatest therapeutic potential.


It is therefore essential to understand the *primary consequences* of R-loop formation on the surrounding chromatin and to identify the R-loops with the greatest therapeutic potential.

A consensus is emerging that at least a subset of those R-loops causes DNA replication-dependent DNA damage that could be at the origin of undesirable genome rearrangements (1). However, the causal relationship between R-loops and DNA damage has mostly been inferred but never rigorously demonstrated. This is because, until now, no technique was available to quickly manipulate R-loop levels *in vivo*. To circumvent this issue, we have developed *iCoRD*, an innovative strategy that relies on modified viral particles to deplete R-loops from human cells *in vivo* under three hours (see below). *iCoRD* puts us in a prime position to address the primary consequences of R-loop loss. Here we will use this approach to understand the contributions of R-loops to the genome instability phenotypes triggered by small-molecule inhibitors of BET-containing proteins such as BRD4 such as dBET6, which show anti-cancer activity in several pre-clinical models. For the first time, we will establish a list of harmful R-loops that could be interesting therapeutic targets.

***In Cellulo* RNase H1 Delivery (iCoRD)**



**Overall strategy**



**Bibliography**

1. Crossley, M.P., Bocek, M. and Cimprich, K.A. (2019) R-Loops as Cellular Regulators and Genomic Threats. *Mol. Cell*, **73**, 398–411.
2. Promonet, A., Padioleau, I., Liu, Y., Sanz, L., Biernacka, A., Schmitz, A.-L., Skrzypczak, M., Sarrazin, A., Mettling, C., Rowicka, M., *et al.* (2020) Topoisomerase 1 prevents replication stress at R-loop-enriched transcription termination sites. *Nat Commun*, **11**, 3940.

3. Wells, J.P., White, J. and Stirling, P.C. (2019) R Loops and Their Composite Cancer Connections. *Trends Cancer*, **5**, 619–631.
4. Lam, F.C., Kong, Y.W. and Yaffe, M.B. (2020) Inducing DNA damage through R-loops to kill cancer cells. *Mol Cell Oncol*, **8**, 1848233.